Gilead Sciences, Inc. GILD NDXSPX

Healthcare · Drug Manufacturers - General · United States

https://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Market & Price

Market Cap

$166.90B

Current Price

$134.43

High / Low (52W)

$154.92 / $103.92

Beta

0.33

Valuation

Stock P/E

18.29

Industry PE

23.65

Forward P/E

14.02

PEG Ratio

2.14

Book Value

$18.93

Price to Book

7.10

P/S

5.61

EV/EBITDA

12.16

Dividend Yield

2.44%

Profitability & Returns

ROCE

22.92%

ROE

43.36%

ROA

13.29%

Profit Margin

30.99%

Op Margin

39.28%

EPS (Latest Qtr)

$1.61

EPS (TTM)

$7.35

Balance Sheet & Liquidity

Debt/Equity

0.95

Quick Ratio

1.54

Current Ratio

1.97

Debt

$22.17B

Total Assets

$59.02B

Current Assets

$18.34B

Working Capital

$6.53B

Ownership

Promoter Holding

0.12%

Chg in Prom Hold

FII / Inst Holding

92.18%

Chg in FII Hold

0.01%

Financial Snapshot

Enterprise Value

$179.18B

Total Revenue (TTM)

$29.74B

EBITDA

$14.74B

Free Cash Flow

$7.93B

Operating Cash Flow

$10.81B

Shares Outstanding

1.24B

Gross Margin

79.37%

Payout Ratio

43.40%

Growth (CAGR)

Revenue 5Y

2.57%

Profit 5Y

22.83%

Revenue (YoY)

4.40%

Earnings (YoY)

54.80%

PROS

Strong return on equity of 43.4%.
Healthy ROCE of 22.9%.
Excellent profit margin of 31.0%.
Profit CAGR of 22.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Period: Metric:

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	GILD Gilead Sciences, Inc. NDXSPX	134.43	18.29	$166.90B	2.44%	22.92%	43.36%	2.57%	22.83%
2	LLY Eli Lilly and Company SPX	1,105.00	39.21	$985.37B	0.63%	38.44%	107.46%	31.69%	48.96%
3	JNJ Johnson & Johnson SPX	225.33	26.11	$542.42B	2.38%	23.13%	26.42%	5.60%	14.32%
4	UNH UnitedHealth Group Incorporated SPX	380.31	28.66	$345.38B	2.32%	9.60%	12.18%	11.35%	-15.69%
5	MRK Merck & Co., Inc. SPX	118.72	33.44	$293.22B	2.86%	20.66%	18.94%	3.12%	7.93%
6	TMO Thermo Fisher Scientific Inc. SPX	492.51	27.11	$183.03B	0.38%	9.17%	13.52%	-0.27%	-1.19%
7	AMGN Amgen Inc. NDXSPX	336.79	23.42	$181.77B	2.99%	18.02%	101.32%	11.77%	5.58%
8	ISRG Intuitive Surgical, Inc. NDXSPXAI	424.64	51.53	$150.39B	-	15.96%	17.23%	17.39%	29.26%
9	PFE Pfizer Inc. SPX	26.18	19.98	$149.21B	6.57%	5.95%	8.31%	-14.80%	-37.20%

Quarterly Results

Figures in USD.

Metric	Sep 2015	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	5.09B	5.65B	5.60B	-	5.28B	5.68B	5.60B	-	5.55B	5.14B	6.58B	-	6.42B	6.22B	7.42B	6.59B	6.26B	7.04B	6.35B	6.60B	7.05B	6.69B	6.95B	7.54B	-	6.67B	7.08B	7.77B	7.92B	6.96B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.54B	1.50B	1.57B	1.62B	1.45B
Gross Profit	7.15B	7.35B	6.49B	6.79B	6.28B	6.14B	5.42B	5.92B	5.37B	4.58B	4.00B	4.34B	4.37B	4.11B	4.24B	4.61B	4.48B	4.11B	4.50B	4.00B	5.35B	5.93B	-	-	-	-	-	-	-	-	-	-	-	-	-	5.13B	5.58B	6.20B	6.30B	5.51B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.64B	2.86B	2.70B	3.31B	2.82B
Operating Income	5.58B	-	4.65B	4.54B	4.40B	-	3.77B	4.25B	3.81B	-	2.15B	2.28B	2.62B	-	2.24B	2.43B	-1.47B	-	2.40B	-2.98B	2.00B	-	2.89B	2.25B	3.84B	197.00M	2.03B	2.84B	1.71B	1.67B	2.62B	-4.32B	2.64B	888.00M	-	2.49B	2.72B	3.50B	2.99B	2.69B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2.60B	3.37B	4.58B	3.02B	3.51B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	260.00M	254.00M	256.00M	255.00M	240.00M
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.65B	2.43B	3.64B	2.08B	2.58B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	334.00M	468.00M	589.00M	-105.00M	559.00M
Net Income	4.60B	4.68B	3.57B	3.50B	3.33B	3.11B	2.70B	3.07B	2.72B	-3.87B	1.54B	1.82B	2.10B	3.00M	1.98B	1.88B	-1.17B	2.70B	1.55B	-3.34B	360.00M	1.55B	1.73B	1.52B	2.59B	19.00M	1.14B	1.79B	1.01B	1.04B	2.18B	-4.17B	1.61B	1.25B	-	1.31B	1.96B	3.05B	2.18B	2.02B
Diluted EPS	3.06	3.18	2.53	2.58	2.49	2.34	2.05	2.33	2.06	-2.96	1.17	1.39	1.60	0.00	1.54	1.47	-0.92	2.12	1.22	-2.66	0.29	1.23	1.37	1.21	2.05	0.02	0.91	1.42	0.80	0.83	1.73	-3.34	1.29	1.00	-	1.04	1.56	2.43	1.74	1.61
R&D Expense	743.00M	-	1.26B	1.48B	1.14B	-	931.00M	864.00M	789.00M	-	937.00M	1.19B	939.00M	-	1.06B	1.16B	4.99B	-	1.10B	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	-	-	-	-	-	-	-	-	-	30.39B	26.11B	22.13B	22.45B	24.69B	27.30B	27.28B	27.12B	28.75B	29.44B
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.66B	6.50B	6.25B	6.23B
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21.62B	20.62B	22.50B	23.21B
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.65B	11.78B	11.91B	11.51B
Operating Income	2.16B	2.68B	3.53B	3.96B	3.79B	4.01B	4.52B	15.27B	22.19B	17.63B	14.12B	8.20B	4.29B	4.07B	9.92B	10.97B	8.84B	10.60B	11.70B
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	8.85B	10.50B	4.43B	13.58B
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	935.00M	944.00M	977.00M	1.02B
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.81B	6.86B	690.00M	9.80B
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.25B	1.25B	211.00M	1.29B
Net Income	1.58B	1.98B	2.64B	2.90B	2.80B	2.59B	3.08B	12.10B	18.11B	13.50B	4.63B	5.46B	5.39B	123.00M	6.22B	4.59B	5.67B	480.00M	8.51B
Diluted EPS	1.64	2.06	2.82	1.66	1.77	1.64	1.81	7.35	11.91	9.94	3.51	4.17	4.22	0.10	4.93	3.64	4.50	0.38	6.78
R&D Expense	-	-	-	-	1.23B	1.76B	2.12B	2.85B	3.01B	5.10B	3.73B	5.02B	9.11B	-	-	-	-	-	-

Compounded Sales Growth

5 Years:	2.57%
1 Year:	4.40%

Compounded Profit Growth

5 Years:	22.83%
1 Year:	54.80%

Stock Price Performance

1 Year:	+25.37%
6 Months:	+7.05%
3 Months:	-9.24%
1 Month:	+4.34%

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2006	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	6.94B	9.70B	11.59B	17.30B	21.24B	22.58B	34.66B	51.72B	56.98B	70.28B	63.67B	61.63B	68.41B	-	63.17B	62.12B	58.99B	59.02B
Current Assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	14.44B	16.09B	19.17B	18.34B
Cash & Equivalents	816.01M	968.09M	1.46B	1.27B	907.88M	9.88B	1.80B	2.11B	10.03B	12.85B	8.23B	7.59B	17.94B	11.63B	6.00B	-	5.41B	6.08B	9.99B	7.56B
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.51B	1.79B	1.71B	1.77B
Receivables	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.78B	4.66B	4.42B	4.91B
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	41.96B	39.38B	39.75B	36.41B
Current Liabilities	-	-	1.22B	1.87B	2.46B	2.51B	4.24B	6.41B	5.76B	9.89B	9.22B	11.63B	10.61B	9.76B	11.40B	-	11.24B	11.28B	12.00B	11.81B
Long Term Debt	-	-	-	-	-	7.61B	7.05B	3.94B	11.92B	21.07B	26.35B	30.80B	24.57B	22.09B	28.64B	-	22.96B	23.19B	24.90B	22.13B
Total Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25.23B	24.99B	26.71B	24.94B
Total Equity	-	-	4.27B	6.37B	5.86B	6.74B	9.30B	11.37B	15.43B	18.53B	18.89B	20.44B	21.39B	22.52B	18.20B	-	21.24B	22.83B	19.33B	22.70B
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.25B	1.25B	1.25B	1.24B

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	1.67B	2.14B	3.08B	2.83B	3.64B	3.19B	3.10B	12.82B	21.25B	17.05B	11.90B	8.40B	9.14B	8.17B	-	9.07B	8.01B	10.83B	10.02B
Investing Cash Flow	-1.30B	-178.82M	-2.22B	-1.94B	3.59B	-11.85B	-254.00M	-1.82B	-12.47B	-11.98B	-16.07B	14.36B	-7.82B	-14.62B	-	-2.47B	-2.27B	-3.45B	-4.79B
Financing Cash Flow	-170.98M	-1.47B	-1.05B	-1.34B	1.76B	563.00M	-2.54B	-3.02B	-5.88B	-9.72B	3.39B	-12.32B	-7.63B	770.00M	-	-6.47B	-5.12B	-3.43B	-7.75B
Capital Expenditure	-	-	-	-	-	-	-134.00M	-	-	-	-	-924.00M	-825.00M	-650.00M	-	-728.00M	-585.00M	-523.00M	-563.00M
Free Cash Flow	-	-	-	-	-	-	2.97B	-	-	-	-	7.48B	8.32B	7.52B	-	8.34B	7.42B	10.30B	9.46B
Net Change in Cash	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	137.00M	616.00M	3.95B	-2.52B
Share Buybacks	487.54M	1.97B	998.50M	4.02B	2.38B	667.00M	582.00M	5.35B	10.00B	11.00B	954.00M	2.90B	1.75B	1.58B	546.00M	1.40B	1.00B	1.15B	1.92B
Dividends Paid	-	-	-	-	-	-	0	0	1.87B	2.46B	2.73B	2.97B	3.22B	3.45B	3.60B	3.71B	3.81B	3.92B	4.00B

Ratios (Annual)

Figures in %.

Metric	Dec 2007	Dec 2008	Dec 2009	Dec 2010	Dec 2011	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	79.3%	76.0%	78.3%	78.8%
Operating Margin %	-	-	-	-	-	-	-	-	-	58.0%	54.1%	37.1%	19.1%	16.5%	36.3%	40.2%	32.6%	36.9%	39.7%
Net Margin %	-	-	-	-	-	-	-	-	-	44.4%	17.7%	24.7%	24.0%	0.5%	22.8%	16.8%	20.9%	1.7%	28.9%
ROE %	-	46.3%	41.4%	49.5%	41.6%	27.9%	27.0%	78.4%	97.7%	71.5%	22.6%	25.5%	23.9%	0.7%	-	21.6%	24.8%	2.5%	37.5%
ROCE %	-	46.9%	45.1%	43.4%	25.6%	23.6%	28.0%	52.8%	53.1%	36.9%	24.1%	15.5%	8.3%	7.1%	-	21.1%	17.4%	22.5%	24.8%

Shareholding Pattern

Insiders

0.12%

Institutions

92.18%

Public Float

92.29%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	9.59%	119.01M	$16.00B
2	Vanguard Capital Management LLC	6.50%	80.65M	$10.84B
3	FMR, LLC	5.79%	71.91M	$9.67B
4	State Street Corporation	4.82%	59.86M	$8.05B
5	Capital World Investors	3.33%	41.28M	$5.55B
6	Vanguard Portfolio Management LLC	2.83%	35.13M	$4.72B
7	JPMORGAN CHASE & CO	2.74%	33.99M	$4.57B
8	Geode Capital Management, LLC	2.39%	29.73M	$4.00B
9	Capital Research Global Investors	2.18%	27.13M	$3.65B
10	Price (T.Rowe) Associates Inc	2.11%	26.25M	$3.53B

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for GILD

No recent headlines available.

GILD · Healthcare